Management ChangeOct 23, 2026, 06:06 AM
Retension Pharmaceuticals Appoints Robert Wong as Chief Accounting Officer
AI Summary
Retension Pharmaceuticals, Inc. announced the appointment of Robert Wong as its new Vice President and Chief Accounting Officer, effective November 2, 2026. Wong, aged 60, has extensive experience in accounting and finance, previously holding senior roles at The Save Mart Companies, Cytokinetics, and Genentech. His compensation package includes an annual base salary of $360,000, eligibility for a discretionary bonus, a $20,000 sign-on bonus, and a stock option award for 25,000 shares.
Key Highlights
- Robert Wong appointed Vice President, Chief Accounting Officer of Retension Pharmaceuticals, effective November 2, 2026.
- Wong brings 30 years of experience, including roles at The Save Mart Companies, Cytokinetics, and Genentech.
- Annual base salary set at $360,000.
- Eligible for a discretionary bonus with a target of 30% of base salary.
- Receives a $20,000 sign-on bonus, subject to continued employment through March 31, 2027.
- Awarded stock options for 25,000 shares, vesting over four years.
Price Impact